Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records

Clinical Therapeutics

Volumn 24, Issue 3, 2002, Pages 378-396

  Boyle, Patrick J ^a   King, Allen Bennett ^b   Olansky, Leann ^c   Marchetti, Albert ^d   Lau, Helen ^d   Magar, Raf ^d   Martin, John ^d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d Health Economics Research   (United States)

Author keywords

Blood lipids; Glycemic control; Hyperglycemia; Hyperlipidemia; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; STATIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036203666     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85040-8     Document Type: Article

References (53)

1. Nonhypoglycemic effects of thiazolidinediones
2. Thiazolidinediones: An update
3. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
4. Medical significance of peroxisome proliferator-activated receptors
5. Hepatic dysfunction associated with troglitazone
6. An autopsy case of troglitazone-induced fulminant hepatitis
7. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
8. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4
9. Hepatocellular injury in a patient receiving pioglitazone
10. Hepatocellular injury in a patient receiving rosiglitazone. A case report
11. Hepatic failure in a patient taking rosiglitazone
12. Rosiglitazone and hepatic failure
13. Rosiglitazone and liver failure
14. Rosiglitazone toxicity
15. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
16. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
17. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
18. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
19. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
20. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
21. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
22. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
23. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
24. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
25. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
26. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
27. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
28. Comparison of the glucose and lipid effects of rosiglitazone (ROS) and pioglitazone (PIO) following conversion from troglitazone (TRO) treatment
29. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
30. A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
31. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
32. Prediction of coronary heart disease using risk factor categories
33. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
34. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
36. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male study
37. Hypertriglyceridemia as a cardiovascular risk factor
38. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
39. The emergence of triglycerides as a significant independent risk factor in coronary artery disease
40. In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element
41. Heart disease in diabetes mellitus
42. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
43. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: Involvement of the VLDL receptor
44. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence
45. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
46. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
47. Randomized, controlled trials, observational studies, and the hierarchy of research designs
48. A comparison of observational studies and randomized, controlled trials